Correlation Engine 2.0
Clear Search sequence regions


  • female (1)
  • humans (1)
  • patients (2)
  • platinum (6)
  • protocol (1)
  • skin testing (3)
  • taxanes (2)
  • taxoids (2)
  • therapies (1)
  • Sizes of these terms reflect their relevance to your search.

    Hypersensitivity reactions (HSRs) to chemotherapy agents can present a serious challenge to treating patients with preferred or first-line therapies. Allergic reactions through an immunologic mechanism have been established for platinum and taxane agents, which are used to treat a wide variety of cancers including gynecologic cancers. Platin HSRs typically occur after multiple cycles of chemotherapy, reflecting the development of drug IgE sensitization, while taxane HSRs often occur on first or second exposure. Despite observed differences between platin and taxane HSRs, drug desensitization has been an effective method to reintroduce both chemotherapeutic agents safely. Skin testing is the primary diagnostic tool used to risk-stratify patients after initial HSRs, with more widespread use for platinum agents than taxanes. Different practices exist around the use of skin testing, drug challenge, and choice of desensitization protocol. Here, we review the epidemiology, mechanism, and clinical presentation of HSRs to platinum and taxane agents, as well as key controversies in their evaluation and management. © 2021. The Author(s).

    Citation

    Lulu R Tsao, Fernanda D Young, Iris M Otani, Mariana C Castells. Hypersensitivity Reactions to Platinum Agents and Taxanes. Clinical reviews in allergy & immunology. 2022 Jun;62(3):432-448

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34338975

    View Full Text